Welcome to our dedicated page for Exagen news (Ticker: XGN), a resource for investors and traders seeking the latest updates and insights on Exagen stock.
Exagen Inc. develops and commercializes autoimmune diagnostic testing products under the AVISE brand. The company’s flagship AVISE CTD test is used by clinicians in evaluating complex rheumatic and autoimmune diseases, including lupus, rheumatoid arthritis and Sjögren’s disease, and its CLIA-certified, CAP-accredited laboratory specializes in rheumatic disease testing.
Recurring news for XGN includes quarterly and annual financial results, AVISE CTD test volume, average selling price, revenue, gross margin and cash updates. Company announcements also cover autoimmune biomarker research, additions to the AVISE testing portfolio, conference participation and corporate updates tied to Exagen’s diagnostics business.
Exagen Inc. (Nasdaq: XGN) has announced that its AVISE test offerings will be available as a contracted service through TRICARE East, managed by Humana Military. This agreement will make AVISE tests accessible to around 6 million beneficiaries, aiming to enhance the diagnosis and monitoring of autoimmune diseases such as lupus. CEO Ron Rocca emphasized the importance of these tests in supporting rheumatologists to improve patient care.
As Exagen seeks to revolutionize the care for autoimmune disease patients, the company expects to gain greater market acceptance of its innovative testing products.
Exagen Inc. (Nasdaq: XGN) will announce financial results for Q2 2020 on July 28, 2020, before market open. The call, hosted by CEO Ron Rocca and CFO Kamal Adawi, is set for 8:00 AM ET (5:00 AM PT). Interested parties can join via phone or webcast through Exagen's investor relations site. A replay will be available until August 4, 2020. Exagen focuses on enhancing care for autoimmune disease patients through advanced testing products, optimizing diagnosis, and treatment strategies.
Exagen Inc. (Nasdaq: XGN) has announced an exclusive license agreement with the Ohio State Innovation Foundation to develop a novel blood test for diagnosing fibromyalgia. This test aims to differentiate fibromyalgia from conditions like rheumatoid arthritis and lupus, potentially addressing the needs of around 12 million undiagnosed patients in the U.S. The technology, based on recent research, could enhance early diagnosis and treatment, thereby reducing misdiagnoses related to autoimmune diseases. Exagen’s commitment is to innovate in autoimmune diagnostics for better patient outcomes.
Exagen Inc. (Nasdaq: XGN) announced a collaborative clinical trial with Duke University to study biomarkers in lupus patients. This prospective study aims to evaluate the AVISE panel and Cell-Bound Complement Activation Products (CB-CAPs) to differentiate between Type 1 and Type 2 systemic lupus erythematosus (SLE). By integrating patient-reported measures, the trial seeks to enhance personal medicine approaches for lupus care, potentially improving patient outcomes. Exagen aims to optimize therapeutic interventions for autoimmune diseases through its proprietary technologies.
Exagen Inc. (Nasdaq: XGN) announced that Ron Rocca, President and CEO, will present at the William Blair 40th Annual Growth Stock Conference on June 9 at 1:20 PM CDT. This year's conference will be virtual, and a live webcast of the presentation will be accessible via the Exagen investor relations website. A replay will be available about one hour after the event concludes. Exagen focuses on transforming care for patients with autoimmune diseases through innovative testing products, including those based on proprietary CB-CAPs technology.
Exagen Inc. (Nasdaq: XGN) reported its financial results for Q1 2020, showing total revenue of $9.6 million, up from $9.3 million in Q1 2019. The company delivered 27,126 AVISE® CTD tests, a 13% increase over the previous year, while the number of ordering healthcare providers grew by 28% year-over-year. However, operating expenses rose to $14.8 million, leading to a net loss of $5.6 million, compared to $2.7 million in Q1 2019. Cash reserves stood at approximately $68.6 million as of March 31, 2020.
Summary not available.